Affiliation:
1. Bristol Myers Squibb, Princeton, NJ, United States
Abstract
Background: The benefit of pathologic complete response (pCR) in early breast cancer (eBC) is not well described in the real-world setting. This study used the nationwide Flatiron Health electronic health record-derived deidentified database to describe treatment patterns and survival outcomes by pCR status after neoadjuvant therapy (NAT) in women with triple-negative or HR+/HER2- eBC. Materials & methods: Observational cohort study analyzing women with eBC who started NAT between 2011 and 2018. Results: 496 women were included in the study; of those, 16.1% achieved pCR, of which 35.7% were triple-negative and 6.1% were HR+/HER2- eBC. More women with triple-negative eBC (95.2%) were exclusively treated with chemotherapy-based NAT versus HR+/HER2- eBC (56.1%). In multivariate analyses from NAT start, not achieving pCR was associated with increased risk of death and progression. Conclusion: pCR status may be a reliable prognostic indicator for survival in these eBC subtypes in the real-world setting.
Subject
Cancer Research,Oncology,General Medicine
Reference39 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. American Cancer Society. Cancer facts & figures 2022 (2022). www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf (Accessed August 2022).
3. Differences in Breast Cancer Survival by Molecular Subtypes in the United States
4. Biological subtypes of breast cancer: Prognostic and therapeutic implications
5. National Cancer Institute. Recent subtype trends in SEER age-adjusted incidence rates, 2010–2019 (2021). https://seer.cancer.gov/explorer/application.html?site=55&data_type=1&graph_type=2&compareBy=subtype&chk_subtype_622=622&chk_subtype_623=623&chk_subtype_620=620&chk_subtype_621=621&hdn_rate_type=1&sex=3&race=1&age_range=1&stage=101&advopt_precision=1&advopt_show_ci=on&advopt_display=2 (Accessed November 2022).